Patents by Inventor Johan Oslob

Johan Oslob has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 9663516
    Abstract: The present invention provides novel bicyclic pyrimidinedione compounds that are useful for the treatment of hypertrophic cardiomyopathy (HCM) and conditions associated with left ventricular hypertrophy or diastolic dysfunction. The synthesis and characterization of the compounds is described, as well as methods for treating HCM and other forms of heart disease.
    Type: Grant
    Filed: December 17, 2015
    Date of Patent: May 30, 2017
    Assignee: MYOKARDIA, INC.
    Inventors: Johan Oslob, Danielle Aubele, Marc Evanchik, Jonathan Charles Fox, Mark Grillo, Brian Kane, Robert McDowell, Yonghong Song, Min Zhong
  • Patent number: 9585883
    Abstract: Provided are novel pyrimidine dione compounds and pharmaceutically acceptable salts thereof, that are useful for the treatment of hypertrophic cardiomyopathy (HCM) and conditions associated with left ventricular hypertrophy or diastolic dysfunction. The synthesis and characterization of the compounds and pharmaceutically acceptable salts thereof, are described, as well as methods for treating HCM and other forms of heart disease.
    Type: Grant
    Filed: October 14, 2015
    Date of Patent: March 7, 2017
    Assignee: MYOKARDIA, INC.
    Inventors: Johan Oslob, Robert Anderson, Danielle Aubele, Marc Evanchik, Jonathan Charles Fox, Brian Kane, Puping Lu, Robert McDowell, Hector Rodriguez, Yonghong Song, Arvinder Sran
  • Publication number: 20160243100
    Abstract: The present invention provides novel 4-methylsulphone-substituted piperidine urea compounds that are useful for the treatment of dilated cardiomyopathy (DCM) and conditions associated with left and/or right ventricular systolic dysfunction or systolic reserve. The synthesis and characterization of the compounds is described, as well as methods for treating DCM and other forms of heart disease.
    Type: Application
    Filed: January 21, 2016
    Publication date: August 25, 2016
    Inventors: Johan Oslob, Danielle Aubele, Jae Kim, Robert McDowell, Yonghong Song, Arvinder Sran, Min Zhong
  • Publication number: 20160176868
    Abstract: The present invention provides novel bicyclic pyrimidinedione compounds that are useful for the treatment of hypertrophic cardiomyopathy (HCM) and conditions associated with left ventricular hypertrophy or diastolic dysfunction. The synthesis and characterization of the compounds is described, as well as methods for treating HCM and other forms of heart disease.
    Type: Application
    Filed: December 17, 2015
    Publication date: June 23, 2016
    Inventors: Johan Oslob, Danielle Aubele, Marc Evanchik, Jonathan Charles Fox, Mark Grillo, Brian Kane, Robert McDowell, Yonghong Song, Min Zhong
  • Publication number: 20160030428
    Abstract: Provided are novel pyrimidine dione compounds and pharmaceutically acceptable salts thereof, that are useful for the treatment of hypertrophic cardiomyopathy (HCM) and conditions associated with left ventricular hypertrophy or diastolic dysfunction. The synthesis and characterization of the compounds and pharmaceutically acceptable salts thereof, are described, as well as methods for treating HCM and other forms of heart disease.
    Type: Application
    Filed: October 14, 2015
    Publication date: February 4, 2016
    Inventors: Johan Oslob, Robert Anderson, Danielle Aubele, Marc Evanchik, Jonathan Charles Fox, Brian Kane, Puping Lu, Robert McDowell, Hector Rodriguez, Yonghong Song, Arvinder Sran
  • Publication number: 20160031862
    Abstract: The present invention provides novel cycloalkyl-substituted pyrimidine dione compounds that are useful for the treatment of hypertrophic cardiomyopathy (HCM) and conditions associated with left ventricular hypertrophy or diastolic dysfunction. The synthesis and characterization of the compounds is described, as well as methods for treating HCM and other forms of heart disease.
    Type: Application
    Filed: October 14, 2015
    Publication date: February 4, 2016
    Inventors: Johan Oslob, Robert Anderson, Danielle Aubele, Marc Evanchik, Jonathan Charles Fox, Brian Kane, Robert McDowell, Hector Rodriguez, Yonghong Song, Arvinder Sran, Pu-Ping Lu
  • Patent number: 9199945
    Abstract: The present invention provides novel cycloalkyl-substituted pyrimidine dione compounds that are useful for the treatment of hypertrophic cardiomyopathy (HCM) and conditions associated with left ventricular hypertrophy or diastolic dysfunction. The synthesis and characterization of the compounds is described, as well as methods for treating HCM and other forms of heart disease.
    Type: Grant
    Filed: June 19, 2014
    Date of Patent: December 1, 2015
    Assignee: Myokardia, Inc.
    Inventors: Johan Oslob, Robert Anderson, Danielle Aubele, Marc Evanchik, Jonathan Charles Fox, Brian Kane, Robert McDowell, Hector Rodriguez, Yonghong Song, Arvinder Sran, Pu-Ping Lu
  • Patent number: 9181200
    Abstract: Provided are novel pyrimidine dione compounds and pharmaceutically acceptable salts thereof, that are useful for the treatment of hypertrophic cardiomyopathy (HCM) and conditions associated with left ventricular hypertrophy or diastolic dysfunction. The synthesis and characterization of the compounds and pharmaceutically acceptable salts thereof, are described, as well as methods for treating HCM and other forms of heart disease.
    Type: Grant
    Filed: June 19, 2014
    Date of Patent: November 10, 2015
    Assignee: Myokardia, Inc.
    Inventors: Johan Oslob, Robert Anderson, Danielle Aubele, Marc Evanchik, Jonathan Charles Fox, Brian Kane, Puping Lu, Robert McDowell, Hector Rodriguez, Yonghong Song, Arvinder Sran
  • Publication number: 20140378464
    Abstract: Provided are novel pyrimidine dione compounds and pharmaceutically acceptable salts thereof, that are useful for the treatment of hypertrophic cardiomyopathy (HCM) and conditions associated with left ventricular hypertrophy or diastolic dysfunction. The synthesis and characterization of the compounds and pharmaceutically acceptable salts thereof, are described, as well as methods for treating HCM and other forms of heart disease.
    Type: Application
    Filed: June 19, 2014
    Publication date: December 25, 2014
    Inventors: Johan Oslob, Robert Anderson, Danielle Aubele, Marc Evanchik, Jonathan Charles Fox, Brian Kane, Puping Lu, Robert McDowell, Hector Rodriguez, Yonghong Song, Arvinder Sran
  • Publication number: 20140378491
    Abstract: The present invention provides novel cycloalkyl-substituted pyrimidine dione compounds that are useful for the treatment of hypertrophic cardiomyopathy (HCM) and conditions associated with left ventricular hypertrophy or diastolic dysfunction. The synthesis and characterization of the compounds is described, as well as methods for treating HCM and other forms of heart disease.
    Type: Application
    Filed: June 19, 2014
    Publication date: December 25, 2014
    Inventors: Johan Oslob, Robert Anderson, Danielle Aubele, Marc Evanchik, Jonathan Charles Fox, Brian Kane, Robert McDowell, Hector Rodriguez, Yonghong Song, Arvinder Sran
  • Patent number: 8771715
    Abstract: The present invention provides compounds and methods for the treatment of LFA-1 mediated diseases. In particular, LFA-1 antagonists are described herein and these antagonists are used in the treatment of LFA-1 mediated diseases. One aspect of the invention provides for diagnosis of an LFA-1 mediated disease and administration of a LFA-1 antagonist, after the patient is diagnosed with a LFA-1 mediated disease. In some embodiments, the LFA-1 mediated diseases treated are dry eye disorders. Also provided herein are methods for identifying compounds which are LFA-1 antagonists.
    Type: Grant
    Filed: January 21, 2011
    Date of Patent: July 8, 2014
    Assignee: Sarcode Bioscience Inc.
    Inventors: Johan Oslob, Wang Shen, Kenneth Barr, Min Zhong
  • Patent number: 8758776
    Abstract: The present invention provides compounds and methods for the treatment of LFA-1 mediated diseases. In particular, LFA-1 antagonists are described herein and these antagonists are used in the treatment of LFA-1 mediated diseases. One aspect of the invention provides for diagnosis of an LFA-1 mediated disease and administration of a LFA-1 antagonist, after the patient is diagnosed with a LFA-1 mediated disease. In some embodiments, the LFA-1 mediated diseases treated are dry eye disorders. Also provided herein are methods for identifying compounds which are LFA-1 antagonists.
    Type: Grant
    Filed: January 21, 2011
    Date of Patent: June 24, 2014
    Assignee: Sarcode Bioscience Inc.
    Inventors: Johan Oslob, Wang Shen, Kenneth Barr, Min Zhong
  • Publication number: 20120232019
    Abstract: The present invention provides compounds and methods for the treatment of LFA-1 mediated diseases. In particular, LFA-1 antagonists are described herein and these antagonists are used in the treatment of LFA-1 mediated diseases. One aspect of the invention provides for diagnosis of an LFA-1 mediated disease and administration of a LFA-1 antagonist, after the patient is diagnosed with a LFA-1 mediated disease. In some embodiments, the LFA-1 mediated diseases treated are dry eye disorders. Also provided herein are methods for identifying compounds which are LFA-1 antagonists.
    Type: Application
    Filed: February 16, 2012
    Publication date: September 13, 2012
    Applicant: SARcode Bioscience Inc.
    Inventors: Thomas Gadek, John Burnier, Johan Oslob, Wang Shen, Kenneth Barr, Min Zhong
  • Publication number: 20070027166
    Abstract: The present invention provides compounds having the formula: wherein A-B together represent one of the following structures: wherein one of is a double bond, as valency permits; and R2, R4, X1A, X2A, X1B, X2B, L1, L2, Y and Z are as defined in classes and subclasses herein, and pharmaceutical compositions thereof, as described generally and in subclasses herein, which compounds are useful as inhibitors of protein kinase (e.g., Aurora), and thus are useful, for example, for the treatment of Aurora mediated diseases.
    Type: Application
    Filed: July 21, 2006
    Publication date: February 1, 2007
    Inventors: Johan Oslob, Chul Yu
  • Patent number: 7115654
    Abstract: The invention provides compounds of Formula I and derivatives thereof, pharmaceutical compositions comprising a compound of Formula I, and methods of treatment utilizing such compounds and compositions: wherein: R1 is chosen from optionally substituted aryl, optionally substituted aralkyl, optionally substituted heteroaryl, and optionally substituted heteroaralkyl; L is a linker; R2 is chosen from optionally substituted aryl, optionally substituted aralkyl, optionally substituted heteroaryl, and optionally substituted heteroaralkyl; and or single stereoisomers, mixtures of stereoisomers, or the pharmaceutically acceptable salts, amides, or esters thereof.
    Type: Grant
    Filed: June 5, 2003
    Date of Patent: October 3, 2006
    Assignee: Sunesis Pharmaceuticals, Inc.
    Inventors: Darin Allen, Bruce Fahr, Johan Oslob, Brian C. Raimundo, Michael J. Romanowski
  • Publication number: 20060211702
    Abstract: The present invention provides compounds having the formula: wherein A-B together represent one of the following structures: n, R1, R2, R3, R4, L1, L2, Y and Z are as defined in classes and subclasses herein, and pharmaceutical compositions thereof, as described generally and in subclasses herein, which compounds are useful as inhibitors of protein kinase (e.g., RAF), and thus are useful, for example, for the treatment of RAF mediated diseases.
    Type: Application
    Filed: December 12, 2005
    Publication date: September 21, 2006
    Inventors: Johan Oslob, Jiang Zhu, Kenneth Barr, Jennifer Cossrow, Brian Raimundo, Hiroko Tanaka
  • Publication number: 20060035908
    Abstract: The present invention provides compounds having the formula: wherein R1, R2, X1, X2, L1, L2, Y and Z are as defined in classes and subclasess herein, and pharmaceutical compositions thereof, as described generally and in subclasses herein, which compounds are useful as inhibitors of protein kinase (e.g., Aurora), and thus are useful, for example, for the treatment of Aurora mediated diseases.
    Type: Application
    Filed: July 15, 2005
    Publication date: February 16, 2006
    Inventors: Willard Lew, Subramanian Baskaran, Johan Oslob, Joshua Yoburn, Min Zhong
  • Publication number: 20050267098
    Abstract: The present invention provides compounds having formula (I): and pharmaceutically acceptable derivatives thereof, wherein R1-R4, n, p, A, B, D, E, L and AR1 are as described generally and in classes and subclasses herein, and additionally provides pharmaceutical compositions thereof, and methods for the use thereof for the treatment of disorders mediated by the CD11/CD18 family of cellular adhesion molecules (e.g., LFA-1).
    Type: Application
    Filed: November 5, 2004
    Publication date: December 1, 2005
    Inventors: Wang Shen, Kenneth Barr, Johan Oslob, Min Zhong
  • Publication number: 20040048895
    Abstract: The invention provides compounds of Formula I and derivatives thereof, pharmaceutical compositions comprising a compound of Formula I, and methods of treatment utilizing such compounds and compositions: 1
    Type: Application
    Filed: June 5, 2003
    Publication date: March 11, 2004
    Inventors: Darin Allen, Bruce Fahr, Johan Oslob, Brian C. Raimundo, Michael J. Romanowski